Immatics Stock (NASDAQ:IMTX)
Previous Close
$7.58
52W Range
$7.46 - $13.77
50D Avg
$10.00
200D Avg
$11.19
Market Cap
$905.91M
Avg Vol (3M)
$588.28K
Beta
0.78
Div Yield
-
IMTX Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX Performance
Peer Comparison
Ticker | Company |
---|---|
MRUS | Merus N.V. |
BCAB | BioAtla, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
INBX | Inhibrx Biosciences, Inc. |
FENC | Fennec Pharmaceuticals Inc. |
REPL | Replimune Group, Inc. |
ALXO | ALX Oncology Holdings Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
LYEL | Lyell Immunopharma, Inc. |
JANX | Janux Therapeutics, Inc. |
KRON | Kronos Bio, Inc. |
KROS | Keros Therapeutics, Inc. |
HRMY | Harmony Biosciences Holdings, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |